The UL97 protein kinase is a serine/threonine kinase expressed by human cytomegalovirus (CMV) that phosphorylates ganciclovir. An investigation of the subcellular localization of pUL97 in infected cells indicated that, early in infection, pUL97 localized to focal sites in the nucleus that transitioned to subnuclear compartments and eventually throughout the entire nucleus. When UL97 kinase activity was eliminated with a K355M mutation or pharmacologically inhibited with maribavir, the expansion and redistribution of pUL97 foci within the nucleus was delayed, nuclear reorganization did not occur and assembly complexes in the cytoplasm failed to form normally. As UL97 kinase and its homologues appear to be functionally related to CDK1, a known regulator of nuclear structural organization, the effects of the UL97 kinase on CDK1 were investigated. Expression of CDK1 in infected cells appeared to be induced by UL97 kinase activity at the level of transcription and was not tied to other virus life-cycle events, such as viral DNA replication or virion assembly. These results suggest that, in addition to phosphorylating CDK1 targets, the UL97 kinase modifies G 2 /M cell-cycle checkpoint regulators, specifically CDK1, to promote virus replication.
INTRODUCTION
Human cytomegalovirus (CMV) is a ubiquitous virus, and infections can be severe in neonates and immunocompromised individuals. Like other herpesviruses, once a host is infected with CMV, the virus establishes a lifelong infection (Britt, 2008; Reeves & Sinclair, 2008) . CMV accounts for about 10 % of all cases of infectious mononucleosis, and the virus has potential links to other diseases, such as atherosclerosis and cancer (Cobbs et al., 2008; GrahameClarke, 2005) . Whilst viral antigens are expressed in a wide variety and grade of tumours, CMV has not been proven to be directly oncogenic, even though it has the ability to elicit both positive and negative regulation on cell-cycle progression (Hertel et al., 2007; Kalejta et al., 2003; Lu & Shenk, 1996; Michaelis et al., 2009) . This virus shares functional properties found in other oncogenic viruses, such as the ability to modify cell-cycle regulators and to increase both RNA and DNA synthesis (Cinatl et al., 2005) .
Approved therapies for CMV infections, such as cidofovir (CDV), all target the viral DNA polymerase (Biron, 2006) . One new antiviral under development is maribavir (MBV), which disrupts virus replication through specific inhibition of the CMV UL97 serine/threonine (Ser/Thr) kinase (Anon., 2007; Biron et al., 2002; Chou, 2008; Prichard, 2009) . Although not essential for replication, viruses deficient in UL97 kinase activity exhibit a severe reduction in virus yield (Gill et al., 2009; Prichard et al., 1999) . As MBV is a highly specific inhibitor of this kinase, it is an excellent pharmacological tool to study the function of the UL97 kinase activity in vitro. Infected cells treated with MBV can complement studies with UL97 kinase-deficient viruses, such as RC314, a recombinant virus with a mutation in the invariant lysine essential for enzymic activity (K355M), and RCD97, a deletion mutant, because they all exhibit highly similar phenotypes (Gill et al., 2009; Prichard et al., 2008) .
As we expound the functions of UL97 kinase, it is clear that this enzyme is important for CMV infection. In the absence of UL97 kinase activity, there is a modest decrease in viral DNA synthesis and late gene expression (Krosky et al., 2003a; Prichard et al., 1999; Wolf et al., 2001) . Degradation of the nuclear lamina and egress of mature capsids is also defective (Hamirally et al., 2009; Krosky et al., 2003a; Marschall et al., 2005; Wolf et al., 2001) . The UL97 kinase is also required to prevent the formation of nuclear aggresomes, which are an innate immune response thought to sequester viral proteins (Kuny et al., 2010; Prichard et al., 2008 Prichard et al., ). et al., 2003 and the pp65 major tegument protein (Chevillotte et al., 2009; Kamil & Coen, 2007) , as well as autophosphorylation of serines and threonines (He et al., 1997) . Many cellular targets of UL97 kinase are also cyclin-dependent kinase (CDK)-related targets, including retinoblastoma protein (Hume et al., 2008; Prichard et al., 2008) , p32 (Marschall et al., 2005) , histone H2B (Baek et al., 2002) and lamin A/C (Hamirally et al., 2009) . CDKs are Ser/Thr kinases involved in cell-cycle checkpoints; their activity requires association with a cyclin regulatory subunit (Liu & Kipreos, 2000) . The UL97 kinase mimics many of the actions of CDKs without the requirement for a regulatory subunit.
A cell requires the maturation/mitosis-promoting factor to enter mitosis, which comprises a heterodimer of cyclin B and CDK1. This factor promotes mitotic events such as chromatin condensation, mitotic spindle formation, lamin network breakdown and Golgi apparatus degradation (Lindqvist et al., 2009) . CMV induces a pseudomitotic state where many of these same events occur without an intervening cytokinesis, including increased levels of cyclin B and CDK1 (Dittmer & Mocarski, 1997; Sanchez et al., 2003) and nuclear lamina breakdown (Hertel et al., 2007) . Like its viral homologues, phosphorylation by the UL97 kinase contributes to disruption of the nuclear lamina to allow viral capsids to exit the nucleus (Cano-Monreal et al., 2009; Hamirally et al., 2009; Lee et al., 2008; Marschall et al., 2005) . The herpes simplex virus type 1 (HSV-1) homologue of pUL97, UL13, interacts with CDK1, so it is possible that pUL97 might alter the expression or function of this CDK to help induce pseudomitotis (Advani et al., 2000) .
As UL97 kinase mimics many of the functions of CDK1, and a UL97 homologue interacts directly with CDK1, we characterized the subnuclear localization of pUL97 during infection and assessed its effects on CDK1 and pseudomitotic morphology. Initially, the subcellular localization of pUL97 in infected cells was characterized to understand where it might be functioning in infected cells. Small foci containing pUL97 appeared very early in virus infection and were subsequently reorganized within the nucleus, and this reorganization was dependent on both kinase activity and viral DNA synthesis. UL97 kinase activity also appeared to support nuclear deformation and altered CDK1 expression, presumably to promote virus replication.
RESULTS

Localization of pUL97 in infected cells
A mAb specific for pUL97 was generated using a synthetic peptide corresponding to the C-terminal 14 aa of pUL97 and the epitope was confirmed to be within the C-terminal 27 aa (Fig. S1 , available in JGV Online). This antibody was used to follow the localization patterns of the UL97 kinase throughout the course of infection. The subcellular localization of pUL97 was evaluated at 1 h post-infection (p.i.) to assess the potential delivery of this protein from the virion tegument into the cell. At this time point, the abundant pp65 tegument protein was localized predominantly to the nucleus, as reported previously (Fig. 1 , middle column, red in merge) (Kalejta, 2008a; Schmolke et al., 1995) . pUL97 was difficult to detect in every infected cell at 1 h p.i. (Fig. 1 , left column, green in merge, and data not shown) and did not always appear different from mockinfected cells stained with this same antibody (Fig. 1. ) These data were not surprising, as pp65 is the most abundant tegument protein in CMV virions, is presumed to be localized to the nucleus upon entry and is present at much higher levels than pUL97 (15.4 % of virion for pp65 versus 0.1 % for pUL97) (Chevillotte et al., 2009; Kalejta, 2008b; Varnum et al., 2004) . However, we cannot conclude that the low levels of pUL97 at 1 h p.i. were due to delivery from the tegument without further investigation.
At 8, 24, 48 and 72 h p.i., pUL97 was localized predominantly in the nuclei of infected cells ( Fig. 1) and staining was clearly distinct from mock-infected cells (Figs S2 and S3) . Distinct intranuclear foci (approximately five per cell) were observed at 8 h p.i. Staining for pUL97 at later stages of infection localized to subnuclear compartments that resembled replication compartments. Nuclear deformation into a 'kidney bean' shape was also noted starting at around 48 h, consistent with reorganization of the nuclear lamina. By 96 h p.i., more diffuse pan-nuclear pUL97 staining was observed and was also present in the centre of the nascent assembly complexes in the cytoplasm (Fig. 1, green arrow) . This pUL97 localization pattern is consistent with packaging as part of the tegument in the mature virus. Intracellular localization of pp65 was included as a control and exhibited a pattern of staining reported previously, beginning with nuclear localization within nucleoli, followed by quantitative flushing from the nucleus at around 48 h p.i. (Arcangeletti et al., 2003; Azzeh et al., 2006; Sanchez et al., 2000 Sanchez et al., , 2007 Schmolke et al., 1995) . Late in infection, pp65 localized just outside the nucleus, within what appeared to be assembly complexes. At 96 h p.i., viral DNA was also detectable within the assembly complex (Fig.  1 , yellow arrow on inset of merge).
When UL97 kinase activity was inhibited with MBV, the subcellular localization of both pp65 and pUL97 was significantly altered. The localization of pUL97 and pp65 was similar to the wild-type (WT) virus at 8 h p.i., yet progression to the larger subnuclear compartments was not observed (Fig. 2) . Later in infection, staining progressed somewhat normally throughout the nucleus, but pUL97 also localized to numerous small foci that clustered near the nuclear periphery. With pp65, there was a noticeable lack of nuclear focal localization at 48 h. At 72 h, pp65 started to flush into the cytoplasm, but there were defects in both nuclear deformation and assembly complex formation. Well-formed assembly complexes were not apparent by 96 h, but abnormal circular blebs surrounded by pp65 were observed in the cytoplasm near the nuclei (Fig. 2, yellow arrows on merge). pUL97 did not appear to be present in the cytoplasm. Generally, levels of both viral proteins were below those in cells infected with the WT virus.
To confirm that the changes in MBV-treated cells were related to reduced kinase activity, the localization of pUL97 was also characterized in cells infected with the kinase-null mutant RC314 (Fig. 3) . The subcellular localization of pUL97 and pp65 appeared to be similar to that observed in the presence of MBV. At 8 h p.i., pUL97 localized to foci in the nucleus that resembled those in MBV-treated cells infected with the WT virus. Very low levels of pp65 were observed in the nuclei at 24 h, although the typical focal localization of pUL97 in the nucleus was apparent. Like the cells treated with MBV, these foci persisted up to 48 h and progression to pan-nuclear staining was delayed. Again, as with MBV treatment, pp65 levels continued to rise but remained distinctly nuclear at 48 h. At 72 h, both cytoplasmic and nuclear distribution of pp65 was observed. Interestingly, by 96 h, a few infected cells exhibited strong nuclear localization of pp65. Like cells treated with MBV, it appeared as though pp65 lined the cytoplasmic blebs (Fig. 3 , 96 h p.i., yellow arrow on merge). These data confirmed the observations with MBV and suggested that the observed defects in the localization of pUL97, aberrant assembly complex formation and deformation of the infected nuclei were related to the absence of kinase activity.
As infected cells treated with MBV and those infected with the RC314 virus exhibited modest reductions in viral DNA, the subcellular localization of pUL97 and pp65 was also characterized in infected cells treated with CDV at a concentration of .20 times its effective concentration (Williams-Aziz et al., 2005) . When viral DNA synthesis was blocked with CDV, prominent foci containing pUL97 formed but did not transition into larger subnuclear compartments or pan-nuclear staining (Fig. 4) . There was also a marked decrease in pp65 expression throughout the Infected monolayers were fixed at the indicated time points and stained for pUL97 (left column, green in merge), pp65 (middle column, red in merge) and nucleic acid (TO-PRO-3 staining; right column, blue in merge). Magnification ¾600.
time course. pUL97 foci were apparent at 8 h and there were approximately two to eight foci per infected cell by 24 h. The relative number appeared to remain stable, yet by 96 h there was a notable reduction in the size of these foci. With viral DNA replication inhibited, infected cells lacked a detectable increase in pp65 expression, and late events, such as formation of the cytoplasmic assembly complexes and nuclear deformation, did not occur.
pUL97 localizes to replication compartments
The localization of pUL97 in infected nuclei resembled that of replication compartments, so co-localization studies were carried out using a mAb to ppUL44 as a marker for CMV replication compartments (Krosky et al., 2003b; Marschall et al., 2003) . In human foreskin fibroblast (HFF) cells infected with the WT virus, ppUL44 started to localize to replication compartments within nuclei by 24 h p.i. (Fig. 5) . At this time, the localization of pUL97 was predominantly nuclear and it started to accumulate in small replication compartments. By 72 and 96 h p.i., the replication compartments were well formed, with pUL97 distributed throughout the compartments, whilst ppUL44 tended to localize more towards the periphery. These data confirmed that pUL97 localizes to the replication compartments late in infection and are consistent with results reported previously by others (Marschall et al., 2003) .
UL97 kinase activity affects the levels of CDK1 in infected cells
Nuclei fail to remodel in the absence of UL97 kinase activity, which is expected if this enzyme is unable to phosphorylate lamins. However, it is also possible that pUL97 could be working in conjunction with CDK1, the cellular kinase that phosphorylates lamin A/C during mitosis, as the HSV-1 homologue to pUL97 interacts with CDK1 (Advani et al., 2003b) . To see whether UL97 kinase activity was connected to CDK1, we first examined CDK1 expression in infected HFF cells in the presence and absence of UL97 kinase activity (Fig. 6) . Expression of the immediate-early proteins IE1-72 and IE2-86 (IE1/ IE2) was used to document virus infection and some inhibition of IE2 expression was observed, as would be expected in response to the inhibition of virus replication (Stenberg et al., 1989) . CDK1 expression was induced by CMV infection, which is consistent with previous findings (Sanchez et al., 2003) , and there was negligible CDK1 in the mock-infected cells, even in the presence of antiviral compounds. Western blotting revealed a modest decrease in the levels of CDK1 in the presence of MBV at both 2 and 20 mM and in cells infected with the kinasenull virus at 72 h p.i. This appeared to be unrelated to virus replication, as a reduction was not seen in the presence of CDV (Fig. 6a) . Similar findings were noted at an earlier time point, even at a higher m.o.i. and with an additional inhibitor, 2-bromo-5,6-dichloro-1-(b-D-ribofuranosyl) benzimidazole (BDCRB), which is structurally related to MBV but prevents cleavage of viral concatameric DNA for packaging into the virion (Williams et al., 2003) (data not shown).
To confirm further the induction of CDK1 by UL97 kinase activity noted on our Western blots, CDK1 expression at 72 h p.i. was quantified using an immunofluorescence assay (IFA). The percentage of infected cells (m.o.i. of 1 p.f.u. per cell), as determined by pUL97 staining, that also had detectable amounts of CDK1 is shown in Fig. 6(b) . Mock-infected cells were included in each experiment, and the low level of CDK1 detected (only 3 % of cells scored positive for CDK1 expression) further supported the resting state of the cells before infection. There was also a statistically significant difference in the kinase-active versus kinase-inactive infectious conditions, further supporting the suggestion that kinase activity is important for CDK1 overexpression. Statistical analysis revealed the difference between mockand WT-infected cells, and mock-and WT+MBV-infected cells to be significant (P¡0.0001), and the differences between WT+MBV-and WT-infected cells (P¡0.0008), WT-and RC314-infected cells (P¡0.0002), and RC314-and mock-infected cells (P¡0.0017) were also all significant. While counting cells that expressed CDK1 and pUL97, it was notable that CDK1 levels in WTinfected cells were qualitatively increased over those cells where UL97 kinase activity was inhibited (Fig. S4) . Infected cells treated with CDV mirrored the CDK1 Infected cells were fixed at the indicated times and mAbs were used to detect pUL97 (left column, green in merge), replication compartments as defined by ppUL44 (middle column, red in merge) and nucleic acid (DAPI staining; right column, blue in merge). Magnification ¾400.
expression in WT-infected cells, which again supported this upregulation being related to an early and kinasespecific event. In summary, the UL97 kinase activity appeared to affect the overall levels of CDK1 in CMV infection.
Transient expression of UL97 kinase increases CDK1 expression
To confirm the link between UL97 kinase activity and CDK1 expression, the effect of transient UL97 kinase expression was examined and representative images are shown for each condition (Fig. 7a) . Although we attempted to perform these transfections in HFF cells, these primary cells were not as amenable to transfection as HEL299 fibroblasts, which were subsequently used for the following experiments. CDK1 was upregulated and its subcellular localization was similar to that of pUL97 in HEL299 cells transiently expressing pUL97. However, when transfected cells were treated with MBV or when cells were transfected with a plasmid expressing the kinase-null mutant, CDK1 was not as apparent. CDK1 was also not readily detected in cells transfected with the empty vector pcDNA3.1 (data not shown). These data supported the earlier findings, and further confirmed that an increase in CDK1 levels is directly related to UL97 kinase activity. To confirm the HEL299 data, we performed a transfection of COS7 cells seeded on coverslips and counted the proportion of cells that expressed both pUL97 and CDK1. These data indicated that there was a statistically significant increase in the percentage of cells with detectable CDK1 expression (P,0.02). In the absence of UL97 kinase activity, cells expressing pUL97 did not induce increased levels of CDK1 (Fig. 7b, c) . These data indicated that UL97 kinase activity increased the expression of CDK1 in transfected HEL299 and COS7 cells.
UL97 kinase activity is required for the CMVinduced transcriptional upregulation of CDK1
As CDK1 is normally at low, static levels in the cell, we wanted to determine whether the increase in protein expression was related to transcriptional upregulation. Quantitative real-time RT-PCR of CDK1, Wee1, cyclin B1 and Fzr1 mRNA levels were evaluated. Cyclin B1, Fzr1 (Cdh1) and Wee1 were included as known regulators of CDK1. Each infectious condition was performed at an m.o.i. of 1 and repeated in triplicate in a 96-well plate, and each experiment was repeated in triplicate. At 24 and 72 h p.i., CDK1 mRNA levels were significantly increased by CMV infection and inhibition of UL97 kinase activity with MBV downregulated transcription of CDK1 (Table 1) . This decrease was kinase specific because it was not observed in the presence of CDV. Interestingly, at 24 h p.i., Wee1 was also dramatically upregulated in infected cells. Significant differences were not observed in Wee1 transcript levels at 72 h, which differs from previous reports (Hertel & Mocarski, 2004) . Inhibition of kinase activity had a modest effect on Fzr1 and cyclin B1 upregulation at 24 h p.i. Whilst Fzr1 did not exhibit any significant differences in regulation at 72 h, cyclin B1 showed a significant increase in the number of transcripts at 72 h. Interestingly, inhibition of the kinase appeared to promote transcription of cyclin B1 at 72 h. Taken together, these data indicated that . Cell extracts were harvested at 72 h, run on a gel and transferred to a nitrocellulose filter. Expression of CDK1 (p34 antibody, clone C-19), IE1/IE2 and actin was detected with mAbs as described in Methods. Both mock-infected (MI) cultures (") and infected cultures (+) were treated with the drug as indicated. The quantities of CDK1 and IE1/IE2 detected were normalized to actin for each sample and expressed as a fraction compared with cells infected with the WT virus, as indicated below the blot. (b) At 72 h p.i. after infection at an m.o.i. of 1, the percentage of CDK1 and pUL97 double-positive cells was determined as the mean±SD of at least three separate experiments. MI cells were counted if positive staining for CDK1 (p34 antibody, clone B-6) was detected. Approximately 75 cells were counted per condition per experiment. All values were significant when compared with WT using Student's t-test: WT/WT+MBV, P,0.0008; WT/K355M, P,0.0002; WT/MI, P,0.0001; WT+MBV/MI, P,0.0001; K355M/MI, P,0.0017; WT+MBV/K355M, P,0.04. UL97 kinase activity is associated with CDK1 overexpression, and that normal kinase activity promotes transcriptional upregulation of CDK1 throughout the course of infection. In addition, kinase activity may also impact on the regulation of other CDK1 regulators.
DISCUSSION
The UL97 kinase has become a therapeutic target of interest because it is required for the phosphorylation of ganciclovir and because of its influence on virus replication. Both MBV and a new mAb specific for pUL97 were used to dissect further the properties of this viral kinase.
The results from these studies indicated that: (i) pUL97 is easily detectable in nuclei by 8 h p.i.; (ii) both UL97 kinase activity and viral DNA replication are required for the nuclear foci to transition into replication compartments; (iii) in the absence of UL97 activity, assembly complexes do not appear to form properly and the deformation of the nucleus does not occur; (iv) in infected cells during CMV infection, UL97 kinase activity promotes the upregulation of a G 2 /M regulator, CDK1, at the transcriptional level; and (v) UL97 kinase activity is sufficient to upregulate CDK1 expression.
The subcellular localization of pUL97 throughout an infected cell and nuclear remodelling depend on its activity. By 8 h, pUL97 is localized exclusively to the nucleus. Foci expand as the infection progresses and become replication compartments, as defined by ppUL44 staining, and this is completely consistent with results reported previously by Marschall et al. (2003) . Late in infection, CMV assembly complexes containing pp65 form in the nook of beanshaped nuclei. The UL97 kinase, along with viral DNA, localizes into the cytoplasmic complexes, consistent with its reported incorporation in virions as a tegument protein (van Zeijl et al., 1997) . Whilst the tegumentation process is not completely understood, our data support previous findings that pUL97 is important for the normal structural progression of virions (Goldberg et al., 2011) .
Inhibition of UL97 kinase activity alters its subcellular distribution. When the UL97 kinase activity is inhibited with MBV or disrupted with a K355M mutation, pUL97 nuclear reorganization is delayed. The redistribution of foci containing pUL97 is also dependent on viral DNA replication, as evidenced by treatment with CDV. Similar changes in the subcellular distribution of pUL97 in response to CDV and NGIC-I and Gö6976 have been reported previously (Marschall et al., 2003) . Like MBV, NGIC-I and Gö6976 are both inhibitors of UL97 kinase activity (Marschall et al., 2001 (Marschall et al., , 2002 Zimmermann et al., 2000) . Thus, results with the mAb were very similar to those obtained with polyclonal antisera to pUL97 (Kamil & Coen, 2007; Michel et al., 1996) . The nuclear foci that persist in the absence of viral DNA replication are interesting. In size and number, the small nuclear foci are similar to Cajal bodies, which would represent areas of high transcriptional activity (Ogg & Lamond, 2002) . It is also possible that other viral proteins are involved in subcellular localization and nuclear remodelling activity of pUL97, as the same localization patterns were not observed in cells transiently expressing pUL97.
The localization of pp65 to assembly complexes late in infection also did not appear to occur in the absence of UL97 kinase activity. Rather, pp65 localized to the periphery of round cytoplasmic blebs just outside the nuclear membrane.
These blebs contained nucleic acid material but did not appear to contain pUL97. These structures are similar to those described by Goldberg et al. (2011) : in the absence of kinase activity, they observed pp65-rich abnormal cytoplasmic aggregates with deformed intra-cytoplasmic membranes that replaced the normal design of the cytoplasmic assembly compartment.
Inhibition of UL97 kinase also prevented the enlargement and 'kidney bean' distortion of the nuclei and is consistent with a previous report by Hamirally et al. (2009) . This structural defect could be due to lack of laminar phosphorylation by UL97 kinase, which would prevent nuclear membrane reorganization and egress of nucleocapsids from the nuclei. This defect could also be supported by CDK1, which also phosphorylates nuclear lamins.
The UL97 kinase has well-documented interactions with many cellular and viral proteins, such as pUL69, that are also targets of CDKs Thomas et al., 2009) . Levels of mitotic regulators, such as cyclin B1 and CDK1, are increased in CMV-infected cells, and the HSV-1 UL97 homologue, UL13, promotes stabilization and activity of CDK1 (Advani et al., 2000; Sanchez et al., 2003) . As we know that: (i) both CDK1 and pUL97 phosphorylate nuclear structural lamins (Hamirally et al., 2009; Kuny et al., 2010; Marschall et al., 2005) , (ii) CDK1 levels are elevated in CMV-infected cells (Jault et al., 1995; Salvant et al., 1998; Sanchez et al., 2003) and (iii) pUL97 homologues interact with CDK1 (Cano-Monreal et al., 2008; , we sought to determine whether there were other links between pUL97 and CDK1. Interestingly, the upregulation of CDK1 in CMV-infected cells appeared to be dependent on UL97 kinase activity (Fig. 6 ). This regulation seemed to be mediated at the level of transcription, as UL97 kinase activity increased the accumulation of CDK1 mRNA (Table 1) . Known regulators of CDK1, namely Fzr1, cyclin B1 and Wee1, were also analysed in an effort to clarify how CDK1 might be regulated. Cyclin B1 is the major regulatory cyclin associated with CDK1 (Miyazaki & Arai, 2007) , and Wee1 phosphorylates and further controls activation of the CDK1/ cyclin B1 complex (Lee et al., 2005) . Fzr1 (also known as Cdh1) is an activator of the mitotic anaphase-promoting complex APC/C and promotes degradation of cyclin B1 (Tran et al., 2010) . Transient expression of pUL97 in uninfected cells also appears to induce the overexpression of CDK1 and is consistent with the idea that UL97 kinase activity induces CDK1 transcription (Fig. 7) . Whilst increased levels of CDK1 transcripts are consistent with increased levels of CDK1, we did not distinguish between increased transcription rates, increased transcript stability or reduced degradation of CDK1 as potential causes of CDK1 accumulation.
Transcriptional induction of CDK1 normally occurs when cells are stimulated to enter the cell cycle from quiescence (G 0 ), as cells mainly regulate CDK1 through post-translational modifications (Onishi et al., 1997; You & Bird, 1995) . The response to CMV infection also varies depending on the state of the infected cell, as cells that are in G 0 /G 1 following infection respond differently from those that are in S/G 2 (Salvant et al., 1998; Zydek et al., 2010) . Part of this cellular response, either cell-cycle progression or arrest, is due to the activity of UL97 kinase. UL97 kinase can phosphorylate retinoblastoma protein, rendering it inactive and promoting entry from G 1 into S (Prichard et al., 2008) . The resulting increase in CDK1 could simply be a result of this well-documented regulatory action (Hume et al., 2008) . However, as the HFF cells were rested for 2 days after reaching confluency, CMV infection could have stimulated CDK1 transcription in these cells by a mechanism similar to that used by shellfish toxin okadaic acid. Many cell checkpoint regulators, including CDK1, have a promoter element called the okadaic acid response element (OARE); when quiescent cells are treated with okadaic acid, there is inhibition of protein phosphatase activity and increased transcription from promoters containing OAREs. The transcriptional activator nuclear factor Y (NF-Y) is normally bound to an OARE; phosphorylation by a number of proteins, such as CDK2, can relieve NF-Y inhibition and regulate the G 2 /M checkpoint (Caretti et al., 2003; Chae et al., 2004; Finch et al., 2001; Liu & Bird, 1998; Manni et al., 2001; Yun et al., 2003) . Other viral proteins with similar function to UL97 kinase, namely adenovirus E1A protein, have been shown to affect CDK1 transcription through this NF-Y mechanism (Padmanabhan et al., 2003) . The data also support the role of NF-Y in the activation of certain promoter regions in HSV-1, so UL97 kinase activity could be mimicking the action of cellular kinases, such as CDK2, to affect both cellular and viral protein regulation (Advani et al., 2003a; Kushnir et al., 2010) . Whilst UL97 kinase activity might be sufficient to induce expression of CDK1, the exact mechanism as to how the kinase does so is unknown.
It is unclear why an increase in CDK1 levels would be beneficial to the virus. It has been suggested that, instead of interacting with a cyclin, CDK1 interacts with the DNA polymerase processivity factor to facilitate replication in HSV-1 (Smith-Donald et al., 2008) . This would certainly suggest a role for viral initiation of CDK1 induction. Another possibility is that the UL97 kinase simply promotes pseudomitosis through upregulation of mitotic regulators. As CMV strain AD169 has been shown to induce extremely high levels of pseudomitosis in the infected cell compared with the Toledo, Towne and TB40/E strains, it would be interesting to note whether these conditions appear with other strains of CMV and might account for published differences in CDK1 regulation by CMV (Hertel et al., 2007; Sanchez et al., 2003) . As additional functions of this viral kinase are elucidated, it is becoming apparent that this kinase impacts on many aspects of CMV replication, which is consistent with the pleiotropic effects observed in the absence of its enzymic activity.
METHODS
Cells, viruses, plasmids and compounds. Primary HFF cells were produced as described previously (Rybak et al., 2000) and HEL299 cells were purchased from ATCC. Cells were propagated routinely as described previously (Prichard et al., 2008) . CMV strain AD169 was obtained from ATCC and virus stocks were prepared as described previously (Prichard et al., 2006) . The construction and characterization of the kinase-inactive pUL97 mutant RC314 has been described previously (Gill et al., 2009) . MBV and BDCRB were kindly provided by John Drach (University of Michigan, Ann Arbor, MI, USA). CDV was a gift from Mick Hitchcock (Gilead Sciences, Foster City, CA, USA). Construction of plasmids expressing V5-epitope-tagged versions of pUL97 and the catalytically inactive K355M mutant have been described elsewhere . A plasmid expressing pUL97 with an N-terminal V5 epitope (pMP92) was modified to delete the C-terminal 27 aa of pUL97 in expression plasmid pMP567.
Antibodies. The CMV-specific mAbs for IE1/IE2 (clone 8B1.2) and pp65 (clone 12D10) were obtained from Chemicon, and the ppUL44 (clone 28-21) mAb was kindly provided by Bill Britt (UAB, Birmingham, AL, USA). An antibody specific for the C terminus of pUL97 (EEDLDGDCRQLFPE) was produced using a synthetic peptide. The resulting mAb (clone 4-1) specifically stained CMVinfected cells and did not recognize epitopes in uninfected cells or in cells infected with the UL97 deletion mutant. This antibody also recognized both variants of pUL97 (Webel et al., 2011) . The phospho-CDK1 (Tyr   15 ) mAb (clone 10A11) was obtained from Cell Signaling Technology. Antibodies specific for CDK1 p34 (clones B-6 and C-19) were acquired from Santa Cruz Biotechnology. Actin mAb (clone AC-40) was from Sigma-Aldrich. The mAb for the V5-epitope tag (Invitrogen) and fluorescently labelled antibodies specific for mouse (isotype-specific), goat and rabbit Igs were obtained from Southern Biotech. HRP-conjugated secondary antibodies for Western blot studies were obtained from Pierce/Thermo Scientific. All commercially available antibodies were used according to the manufacturer's recommendations, whilst the antibodies obtained from Dr Britt and the pUL97 antibody were diluted 1 : 100 for use.
Transient transfection. Plasmid DNA was transiently transfected into cells to express either the UL97 kinase (pMP92) or the kinaseinactivated mutant protein (pMP307). Using a kit designed for primary cells, HEL299 cells were transfected with 3 mg of each plasmid according to the Lonza Nucleofector kit protocol for normal human adult dermal fibroblasts. MBV was added at 1 h posttransfection to the required wells at a concentration of 20 mM. Cells were incubated at 37 uC in 5 % CO 2 for 36 h before fixation for IFA analysis. Transfection of pUL97-expressing plasmids and visualization of overall protein expression in COS7 cells was performed on coverslips, as described previously (Prichard et al., , 2008 .
Indirect IFA. Confluent monolayers of primary HFF cells were rested in 2 % FBS for 2 days prior to infection. All infections were performed in medium containing 2 % FBS at an m.o.i. of 1 unless otherwise noted. Inocula were aspirated, the monolayers washed and fresh medium was added with the addition of MBV, CDV or BDCRB as indicated. To visualize protein expression and localization in cells, monolayers were washed twice with PBS and fixed with freshly made 4 % paraformaldehyde in PBS for 1 h at ambient temperature. Fixed cells were then permeabilized for 30 min using 0.2 % Triton X-100 and blocked in 0.4 % fish skin gelatine for 1 h at ambient temperature. Primary antibodies were diluted according to the manufacturers' recommendations in 0.4 % fish skin gelatine in PBS and incubated for 1 h at ambient temperature. Coverslips or slides were washed gently with PBS and incubated with FITC-, Texas red-or TRITC-conjugated secondary antibody for 1 h. Coverslips were mounted using SlowFade Antifade Reagent with DAPI (Invitrogen) and visualized using 6400 magnification under an Olympus BX41 microscope. Slides for confocal analysis were prepared as above, except that nuclear staining was performed with TO-PRO-3 iodide (642/661; Molecular Probes/Invitrogen), mounted using SlowFade antifade reagent and visualized under oil immersion at 6600 magnification using an Olympus BX51 Confocal Microscope and Fluoview Software (version 5.0; Olympus). To evaluate the effect of pUL97 on CDK1, at least three fields from each coverslip were photographed and cells that co-expressed each protein were counted. Cells were scored as positive for pUL97 and CDK1 if they exhibited visible staining.
Quantitative real-time RT-PCR. Monolayers of infected HFF cells in 96-well plates were harvested at 24 and 72 h p.i. using an SV 96 Total RNA Isolation System (Promega). cDNA was produced using a High Capacity RNA-to-cDNA kit (Applied Biosystems). Each infectious condition was performed at an m.o.i. of 1 and was repeated in triplicate within the plate. Each experiment was then repeated in triplicate (three 96-well plates in all). Primer and TaqMan probes specific for pUL97, RPL13a, CDK1, Wee1, Fzr1 and cyclin B1 were designed using Primer Express software version 3.0 (Applied Biosystems). Primers were purchased from Integrated DNA Technologies and probes [6-carboxyfluorescein (FAM)/tetramethylrhodamine (TAMRA)] were obtained from Applied Biosystems (Supplementary Table S1 ). Reactions containing 250 ng cDNA were performed in triplicate using an ABI 7300 RealTime PCR System using a TaqMan Universal PCR Master Mix (Applied Biosystems). Statistical analyses of the data were performed using a paired Student's t-test. The fold up-or downregulation was determined using the method described by Pfaffl (2001) using the cellular transcript for RPL13a to normalize the data. Infections were confirmed using primers for IE1/IE2 using Power SYBR Green real-time PCR Master Mix technologies (Applied Biosystems).
Polyacrylamide gels and Western blotting. Cells were infected as described for IFA. At the noted time points, cells were washed twice with ice-cold PBS and cold RIPA buffer was added to the wells. Cells underwent three 280 uC freeze-thaw cycles to aid in complete membrane lysis. Cells were scraped from each well and run through a 25 g sterile needle. Extracts were centrifuged at 5600 g at 4 uC for 10 min, and total supernatant protein concentration was determined using a BCA Protein Assay (Pierce/Thermo Scientific). Twenty-five micrograms of each sample was analysed by Tris/glycine SDS-PAGE (7.5 % acrylamide). Proteins were transferred to a nitrocellulose membrane using the Bio-Rad semi-dry transfer method. Blocking was performed for 1 h at 25 uC in Pierce StartingBlock T20 blocking buffer and membranes were incubated overnight at 4 uC in 5 ml blocking buffer containing antibody, diluted according to the manufacturer's recommendation. Membranes were washed five times with gentle shaking in PBS with 0.1 % Tween 20, and secondary antibodies conjugated to HRP were diluted in 5 ml blocking buffer and incubated for 2 h at 4 uC. HRP was detected using SuperSignal West Dura Extended Duration Substrate (Pierce/Thermo Scientific).
